RIABNI (rituximab-arrx) is a CD20-directed cytolytic antibody indicated for the treatment of...Adult patients with non-Hodgkin’s Lymphoma (NHL)...Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent.

RIABNI (rituximab-arrx) is a CD20-directed cytolytic antibody indicated for the treatment of...Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy...Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or other anthracycline-based chemotherapy regimens.

Adult, anti-CD20 treatment naïve patients diagnosed with grade 1, 2, or 3a follicular B-cell NHL expressing CD20 were randomized 1:1 to receive a 375 mg/m2 infusion of either ABP 798 or rituximab RP once weekly...Overall, 96 patients (78.0%) in the ABP 798 group and 87 patients (70.2%) in the rituximab RP group had a best ORR by week 28; the point estimate of RD of ORR between treatment groups (ABP 798 − rituximab RP) from the generalized linear model adjusting for stratification factors was 7.7%....Of the 256 randomized patients, 254 were treated with ABP 798 (n = 128; 100%) or rituximab RP (n = 126; 98.4%); 96 (78.0%) patients in the ABP 798 group and 87 (70.2%) in the rituximab RP group had a best ORR by week 28.